Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (1003)	11/18/1998 12:34:00 AM
From: SOROS	Respond to of 1185

Quality will win out. I have patience with NRT. Step by step they are climbing toward the goal. I don't really care if the stock goes up 50% each year or 200% in four. If they become the drug company I expect, we will be rewarded for patience. You may make more money trading for a year or two, but I will dollar cost average to accumulate. If NRT becomes a company with multiple drugs on the market, who do you think will hold more shares when it trades considerably higher -- the one accumulating or the trader? I remain, SOROS

To: David Culver who wrote (1003)	11/18/1998 12:40:00 AM
From: Ms. Forthright	Read Replies (1) \| Respond to of 1185

This is indeed good news! The arrangement with Roche I believe was limited to atrial fibrillation. This leaves venticular arrhythmia, in which Nortran has an advanced program. In my opinion it is good news for several reasons: 1. Astra is huge and clearly they know what they are doing. Excellent company to be in partnership with. 2. This provides validation of Nortran's approach and drug pipeline. 3. Potential for these compounds is huge, but so is the cost of bringing them to market. It is necessary to have the financial backing of a major pharma for cardiovascular agents. 4. With both Roche and Astra involved with similar drugs there may be an impetus to accelerate development programs and clinical trials.